Lin Yang

This study identifies therapeutic options, biomarkers, and resistance mechanisms for high-grade gliomas using genomic, transcriptomic profiling, and drug testing in patient-derived models.

This study designs a de novo peptide modulator, ELIXIR, that inhibits pathogenic late sodium current in NaV channels, reversing dysfunction in cardiac arrhythmias and epilepsy models.

The paper identifies a potent MET degrader using live cell imaging, showing it is more effective than existing PROTACs.